Cargando…

Pasireotide—a novel somatostatin receptor ligand after 20 years of use

Pasireotide, a novel multireceptor-targeted somatostatin receptor ligand (SRL) is characterized by a higher affinity to somatostatin receptor type 5 than type 2, unlike first-generation SRLs. Because of the broader binding profile, pasireotide has been suggested to have a greater clinical efficacy i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bolanowski, Marek, Kałużny, Marcin, Witek, Przemysław, Jawiarczyk-Przybyłowska, Aleksandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9156514/ https://www.ncbi.nlm.nih.gov/pubmed/35067849 http://dx.doi.org/10.1007/s11154-022-09710-3

Ejemplares similares

The Effect of 6 Months’ Treatment With Pasireotide LAR on Glucose Metabolism in Patients With Resistant Acromegaly in Real-World Clinical Settings
por: Witek, Przemysław, et al.
Publicado: (2021)

The Relationship between the Burden of Acromegaly, Associated Comorbidities, Complications and Disease Status
por: Elbaum, Michał, et al.
Publicado: (2023)

Pituitary Disorders and Osteoporosis
por: Bolanowski, Marek, et al.
Publicado: (2015)

Ghrelin and Leptin Concentrations in Patients after SARS-CoV2 Infection
por: Kuliczkowska-Płaksej, Justyna, et al.
Publicado: (2023)

Patients with Active Acromegaly are at High Risk of 25(OH)D Deficiency
por: Halupczok-Żyła, Jowita, et al.
Publicado: (2015)

Complications and Comorbidities of Acromegaly—Retrospective Study in Polish Center
por: Rolla, Małgorzata, et al.
Publicado: (2021)

Association between FTO gene polymorphisms and HDL cholesterol concentration may cause higher risk of cardiovascular disease in patients with acromegaly
por: Franczak, Aleksandra, et al.
Publicado: (2017)

FTO Gene Polymorphisms and Their Roles in Acromegaly
por: Jawiarczyk-Przybyłowska, Aleksandra, et al.
Publicado: (2023)

Editorial: Health-Related Complications of Acromegaly
por: Bolanowski, Marek, et al.
Publicado: (2020)

Importance of Illness Acceptance Among Other Factors Affecting Quality of Life in Acromegaly
por: Jawiarczyk-Przybyłowska, Aleksandra, et al.
Publicado: (2020)

Is H19 RNA a Useful Marker of Acromegaly and Its Complications? A Preliminary Study
por: Rolla, Małgorzata, et al.
Publicado: (2023)

Association of Vitamin D Receptor Polymorphisms With Activity of Acromegaly, Vitamin D Status and Risk of Osteoporotic Fractures in Acromegaly Patients
por: Jawiarczyk-Przybyłowska, Aleksandra, et al.
Publicado: (2019)

The Influence of SARS-CoV-2 Infection on the Thyroid Gland
por: Piekarska, Aleksandra, et al.
Publicado: (2023)

Estrogens Modulate Somatostatin Receptors Expression and Synergize With the Somatostatin Analog Pasireotide in Prostate Cells
por: Rossi, Valentina, et al.
Publicado: (2019)

Trabecular Bone Score and Osteoprotegerin as Useful Tools in the Assessment of Bone Deterioration in Acromegaly
por: Jawiarczyk-Przybyłowska, Aleksandra, et al.
Publicado: (2022)

Pasireotide-resistant Refractory Cushing's Disease without Somatostatin Receptor 5 Expression
por: Mizuno, Tomoko, et al.
Publicado: (2021)

Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
por: Samson, Susan L., et al.
Publicado: (2021)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

THU054 A Post Hoc Analysis Of The Phase IV B2219 Study To Determine Predictive Factors For Hyperglycemia During Treatment With Pasireotide
por: Samson, Susan Leanne, et al.
Publicado: (2023)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

MON-LB079 A Multicenter, Randomized, Open-Label, Phase IV Study Investigating Management of Pasireotide-Associated Hyperglycemia with Incretin-Based Therapy or Insulin in Patients with Acromegaly or Cushing's Disease (CD)
por: Samson, Susan, et al.
Publicado: (2019)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

Real-World Experience With Pasireotide Lar in Acromegaly Resistant to First-Generation Somatostatin Analogs: A Single Center 1-Year Observation
por: Stelmachowska-Banas, Maria, et al.
Publicado: (2021)

Acromegaly Caused by Ectopic Growth Hormone Releasing Hormone Secretion: A Review
por: Zendran, Iga, et al.
Publicado: (2022)

AIP-mutated acromegaly resistant to first-generation somatostatin analogs: long-term control with pasireotide LAR in two patients
por: Daly, Adrian F, et al.
Publicado: (2019)

Pasireotide: a novel treatment for patients with acromegaly
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Structural insights into ligand recognition and selectivity of somatostatin receptors
por: Zhao, Wenli, et al.
Publicado: (2022)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

Medical treatment of Cushing’s disease with concurrent diabetes mellitus
por: Mehlich, Anna, et al.
Publicado: (2023)

Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues
por: Wolin, Edward M, et al.
Publicado: (2015)

A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant
por: Ramalingam, Sendhilnathan, et al.
Publicado: (2021)

Pasireotide in the Personalized Treatment of Acromegaly
por: Puig-Domingo, Manel, et al.
Publicado: (2021)

Etiology, baseline clinical profile and comorbidities of patients with Cushing’s syndrome at a single endocrinological center
por: Stachowska, Barbara, et al.
Publicado: (2020)

Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant
por: Chiloiro, Sabrina, et al.
Publicado: (2021)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers
por: Golor, Georg, et al.
Publicado: (2012)

SUN-LB075 Effects of Pegvisomant and Pasireotide LAR on Incidence of Vertebral Fractures in Patients with Acromegaly Resistant to Treatment with First-Line Somatostatin Analogs
por: Chiloiro, Sabrina, et al.
Publicado: (2019)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_91qi2ouho9p0sq0fg2ikf8m2r5